Armistice Capital’s BioNTech BNTX Stock Holding History

Armistice Capital’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-36,000	Closed	-$4.48M	–	229
2023 Q1	$4.48M	Sell	36,000 -4,000	-10%	-$549K	0.06%	109
2022 Q4	$6.01M	Sell	40,000 -116,000	-74%	-$17.9M	0.1%	91
2022 Q3	$21M	Buy	156,000 +56,000	+56%	+$8.56M	0.37%	58
2022 Q2	$14.9K	Buy	100,000 +25,000	+33%	+$3.82M	0.26%	70
2022 Q1	$12.8M	Buy	75,000 +7,000	+10%	+$1.18M	0.25%	68
2021 Q4	$17.5M	Buy	68,000 +16,000	+31%	+$4.38M	0.29%	77
2021 Q3	$14.2M	Sell	52,000 -12,000	-19%	-$3.81M	0.24%	78
2021 Q2	$14.3M	Sell	64,000 -212,000	-77%	-$40M	0.26%	79
2021 Q1	$30.1M	Buy	276,000 +40,000	+17%	+$4.25M	0.69%	42
2020 Q4	$19.2M	Sell	236,000 -100,000	-30%	-$9.82M	0.65%	45
2020 Q3	$23.3M	Buy	+336,000	New	+$24.1M	0.84%	44

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital's BNTX Position: Q2 2023 in Review

Armistice Capital sold out of BioNTech (BNTX) in Q2 2023, closing a stake of 36,000 shares — an estimated $4.48M sold.

Armistice Capital first reported a position in BNTX in Q3 2020 and held it in 11 quarters. The position peaked at $30.1M in Q1 2021. 253 funds tracked by Wall St. Rank hold BNTX as of Q2 2023.

Armistice Capital reported no remaining BioNTech position as of Q2 2023 after selling out during the quarter.
Armistice Capital sold 36,000 BioNTech shares in Q2 2023, an estimated $4.48M.
Armistice Capital first reported a position in BioNTech in Q3 2020 and held it in 11 quarters.
Armistice Capital's BioNTech position peaked at $30.1M in Q1 2021.
253 funds tracked by Wall St. Rank held BioNTech as of Q2 2023.

Based on Armistice Capital's 13F filing for Q2 2023, filed 14 Aug 2023.